The New England Journal of Medicine December 30, 2020

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

L.R. Baden, H.M. El Sahly, B. Essink, et al.

Bottom Line

In a phase 3 trial, the mRNA-1273 (Moderna) vaccine demonstrated 94.1% efficacy at preventing symptomatic COVID-19 illness, including severe disease, with a favorable safety profile.

Key Findings

1. Symptomatic COVID-19 occurred in 185 participants in the placebo group (56.5 per 1000 person-years) and 11 in the mRNA-1273 group (3.3 per 1000 person-years), resulting in a vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001) [1.1].

2. Severe COVID-19 occurred in 30 participants, with one fatality; all 30 severe cases were in the placebo group.

3. Vaccine efficacy was similar across key secondary analyses, including in participants 65 years of age or older, and in those with evidence of SARS-CoV-2 infection at baseline.

4. Moderate, transient reactogenicity occurred more frequently in the mRNA-1273 group, while serious adverse events were rare and similar in incidence between both groups.

Study Design

Design

RCT

Observer-Blind

Sample

30,420

Patients

Duration

2 mo

Median

Setting

Multicenter, US

Population Adults 18 years of age or older in medically stable condition who were at high risk for SARS-CoV-2 infection or its complications.

Intervention Two intramuscular injections of the mRNA-1273 vaccine (100 μg) administered 28 days apart.

Comparator Two intramuscular injections of saline placebo administered 28 days apart.

Outcome Prevention of a first occurrence of symptomatic COVID-19 with onset at least 14 days after the second injection in the per-protocol population (seronegative at baseline).

Study Limitations

• Theshortmedianfollow-upofapproximately2monthsatthetimeofprimaryanalysislimitedtheassessmentoflong-termsafetyanddurabilityofprotection[1.1].

• The primary analysis did not initially provide definitive data on the vaccine's efficacy against asymptomatic infection or its impact on viral transmission.

• Specific populations, such as pregnant women and children, were excluded from this initial phase 3 study.

Clinical Significance

The COVE trial provided definitive clinical evidence that the mRNA-1273 vaccine was highly effective and safe, supporting its rapid Emergency Use Authorization (EUA) and serving as a critical intervention to reduce morbidity and mortality during the global COVID-19 pandemic.

Historical Context

Launched in July 2020 as part of Operation Warp Speed, the trial tested a novel lipid nanoparticle-encapsulated mRNA platform encoding the prefusion stabilized spike protein of SARS-CoV-2. The unprecedented speed from viral sequencing to phase 3 completion and publication marked a historic milestone in vaccinology.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the mRNA-1273 vaccine utilize the host cellular machinery to generate immunity against SARS-CoV-2, and why is lipid nanoparticle encapsulation essential for this mechanism?

Key Response

This question targets high-yield basic science concepts for board exams. It requires the student to explain that the vaccine delivers mRNA which is translated by host ribosomes into the SARS-CoV-2 spike protein. The lipid nanoparticle (LNP) is critical because it protects the fragile mRNA from rapid degradation by extracellular RNases and facilitates entry into the host cell via endocytosis.

Resident

A patient presents with fever, fatigue, and myalgias 24 hours after receiving their second dose of the mRNA-1273 vaccine. How do you clinically differentiate between expected vaccine reactogenicity and a true incidental SARS-CoV-2 infection, and how does this impact your infection control management?

Key Response

Residents frequently manage acute post-vaccination presentations. This highlights the need to distinguish systemic reactogenicity (common within 24-48 hours post-dose 2) from true infection, which might present with respiratory symptoms or anosmia. The clinical distinction dictates whether to isolate the patient and order PCR testing, avoiding unnecessary resource utilization while maintaining strict infection control.

Fellow

The phase 3 trial demonstrated 94.1% efficacy but largely excluded patients on active immunosuppressive therapies. How should we interpret this efficacy data for patients with systemic autoimmune diseases on B-cell depleting therapies (e.g., rituximab), and what are the alternative immunological pathways that might still provide clinical benefit?

Key Response

Fellows manage complex, subspecialty populations. This requires understanding that while neutralizing antibody responses may be blunted in patients on CD20 inhibitors, the mRNA vaccine may still elicit a robust T-cell response, potentially protecting against severe disease even if the primary endpoint of the trial (prevention of symptomatic infection) is compromised in this cohort.

Attending

The trial's primary endpoint was the prevention of symptomatic COVID-19, not asymptomatic infection. When counseling vaccine-hesitant patients, how do you explain the difference between absolute risk reduction and relative risk reduction in the context of this trial, and how does the uncertainty regarding asymptomatic transmission alter post-vaccination behavioral guidance?

Key Response

Attendings must translate complex trial data into actionable patient counseling. This addresses the common clinical challenge of explaining trial endpoints (94.1% relative risk reduction vs a smaller absolute risk reduction depending on background prevalence) and emphasizes the early teaching point that preventing symptomatic disease does not perfectly equate to sterilizing immunity, thereby guiding continued public health precautions.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The mRNA-1273 phase 3 trial utilized an observer-blinded design. What are the specific methodological justifications for this over a double-blinded design in vaccine trials, and how might participant unblinding due to severe local or systemic reactogenicity introduce bias into the evaluation of the primary efficacy endpoint?

Key Response

This tests advanced research methodology. Observer-blinding is used because the vaccine and placebo may have visually distinct preparation requirements. Furthermore, high reactogenicity in the vaccine arm can functionally unblind participants, potentially leading to ascertainment bias or risk compensation behaviors, which are critical methodological threats to evaluate when interpreting self-reported symptom triggers for PCR testing.

Journal Editor

The trial relied heavily on passive surveillance, requiring participants to self-report symptoms to trigger a SARS-CoV-2 PCR test. From an editorial perspective, how does this passive case ascertainment strategy threaten the internal validity of the efficacy estimate compared to active, scheduled swabbing, and what statistical sensitivity analyses would a reviewer demand to address this?

Key Response

Editors focus on critical appraisal and threats to validity. If vaccinated participants assume they are immune and ignore mild symptoms, while placebo participants are hyper-vigilant, case ascertainment bias could artificially inflate the efficacy estimate. A rigorous review would demand analyses of protocol adherence and potentially look at seroconversion rates to non-spike nucleocapsid proteins to estimate missed asymptomatic or mild infections.

Guideline Committee

Given the 94.1% efficacy and favorable safety profile demonstrated in this trial, how should bodies like the ACIP apply the GRADE framework to issue an Emergency Use Authorization recommendation, and what specific post-marketing surveillance data must be mandated to update future guidelines regarding booster doses and variant efficacy?

Key Response

Guideline committees must weigh the certainty of evidence against urgent public health needs. This question explores how the ACIP uses GRADE to evaluate the high certainty of short-term efficacy and safety against the low certainty of long-term durability and rare adverse events (like myocarditis, discovered later). It emphasizes the transition from static trial data to 'living' guidelines that must adapt to waning immunity and viral evolution.

Clinical Landscape

Noteworthy Related Trials

2020

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

n = 43,548 · NEJM

Tested

BNT162b2 mRNA vaccine in two doses

Population

Adults and adolescents aged 16 years or older

Comparator

Placebo

Endpoint

Confirmed Covid-19 at least 7 days after second dose

Key result: The vaccine was 95 percent effective in preventing Covid-19. It showed a favorable safety profile with mostly mild-to-moderate transient reactogenicity.

2021

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine

n = 23,848 · Lancet

Tested

ChAdOx1 nCoV-19 viral vector vaccine in two doses

Population

Adults aged 18 years and older

Comparator

MenACWY vaccine or placebo

Endpoint

Symptomatic COVID-19 at least 14 days after second dose

Key result: Overall vaccine efficacy was 70.4 percent against symptomatic disease. It offered complete protection against COVID-19 hospitalization and death.

2021

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

n = 44,325 · NEJM

Tested

Single dose of Ad26.COV2.S viral vector vaccine

Population

Adults aged 18 years and older

Comparator

Placebo

Endpoint

Moderate to severe-critical Covid-19 at least 14 and 28 days after administration

Key result: The single-dose vaccine was 66.9 percent effective against moderate to severe-critical Covid-19. It provided robust protection against hospitalization and death.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis